Nitroxoline for prevention and treatment of coronavirus disease

Summary of the technology

University of Ljubljana has repurposed Nitroxolin for the prevention and treatment of diseases caused by coronaviruses, in particular SARS-CoV-2. A significant advantage of nitroxoline over other candidate drugs for the treatment of covid-19 (repurposing drugs – amantadine, teicoplanin) is that the mechanism of action on the target has been extensively investigated. Our process can additionally generate a variety of compounds with improved antiviral activity.

University of Ljubljana

Details of the Technology Offer

The SARS-CoV-2 (covid-19) pandemic has caused one of the worst health crises in recent history. The spike protein of SARS-CoV-2 has been suggested to be processed by serine peptidase, resulting in membrane fusion and direct release of viral genetic material to the host cell. Our invention is intended for the prevention and treatment of diseases caused by coronaviruses, in particular SARS-CoV-2.

Cathepsin B inhibitors, in particular 8-hydroxyquinoline derivatives inactivate with superior efficacy host and/or viral proteases, involved in SARS-CoV-2 cell entry and viral replication. Nitroxoline, used in clinical practice in the treatment of urinary tract infections, expresses its antibiotics activity as a metal ion chelator. Synergistic activity of cathepsin B inhibition and metal ion chelation result in the strong potential of Nitroxoline and other 8-hydroxyquinoline cysteine protease inhibitors against SARS-CoV-2.

A significant advantage of nitroxoline over other candidate drugs for the treatment of covid-19 (repurposing drugs – amantadine, teicoplanin) is that the mechanism of action on the target has been extensively investigated. Our process can additionally generate a variety of compounds with improved antiviral activity.

Current development status

Working prototypes

Applications

Health sector. Pharmaceutical industry.

Desired business relationship

  • Technology selling
  • Patent licensing
  • Technology development

Intellectual property status

  • Patent already applied for
  • Patent application number :LU102267

Related Keywords

  • Pharmaceutics
  • Covid-19
  • membrane
  • infection
  • treatment
  • antiviral
  • viral
  • clinical practice
  • protease
  • repurposing
  • inhibitors
  • ion
  • coronavirus
  • sars
  • fusion
  • pharmaceutical industry
  • covid
  • chelation
  • chelators
  • cysteine
  • derivative
  • drug
  • inhibition
  • metal ion
  • pandemic
  • protease inhibitor
  • serine
  • spike protein
  • terget
  • viral protease
  • viral replication

About University of Ljubljana

The Knowledge Transfer Office of the University of Ljubljana acts as a bridge between the fields of research and business. We support researchers and students with ideas and potential innovations, while also acting as an access point for companies on the lookout for technology, knowledge, or project partnerships.

Our main objective is to encourage and support various forms of knowledge transfer to the business sector and thus society.

Simona Rataj

Never miss an update from Simona Rataj

Create your free account to connect with Simona Rataj and thousands of other innovative organizations and professionals worldwide

Simona

Send a request for information
to Simona

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support